肝爽颗粒联合恩替卡韦抗病毒治疗乙肝肝硬化的临床效果
房荣，马小勇
（陕西省延安市人民医院感染科，陕西 延安，715700）
浏览次数：481次 下载次数：277次
摘要：
目的 探讨肝爽颗粒联合恩替卡韦抗病毒治疗乙肝肝硬化患者的临床效果。方法 将我院收治的132 例乙肝肝硬化患者按 照入院时间分为对照组和观察组，每组66 例。对照组患者给予恩替卡韦抗病毒治疗，观察组患者给予肝爽颗粒+恩替卡韦抗病 毒治疗。比较两组患者的临床效果。结果 观察组患者的治疗总有效率为95.5%，明显高于对照组的81.8%（P<0.05）；治疗后，两 组患者的AST、ALB、ALT、TBIL、LN、PCⅢ、Ⅳ-C 及HA 水平明显优于治疗前，且观察组明显优于对照组（P<0.05）。结论 应用肝 爽颗粒联合恩替卡韦抗病毒治疗乙肝肝硬化可更好地改善患者的肝功能，可取得满意的临床效果，值得临床推广应用。
关键词：肝爽颗粒；恩替卡韦；乙肝肝硬化
中图分类号：R512.62；R575.2文献标志码：A文章编号：2096-1413(2018)03-0117-02
Clinical effect of Ganshuang particles combined with entecavir on antiviral therapy of hepatitis B cirrhosis
FANG Rong, MA Xiao-yong
(Infectious Disease Department, Yan``an People``s Hospital, Yan``an 715700, China)
ABSTRACT: Objective To investigate the clinical effect of Ganshuang particles combined with entecavir on antiviral therapy of hepatitis B cirrhosis. Methods A total of 132 hepatitis B cirrhosis patients admitted in our hospital were selected and divided into control group and observation group according to the admission sequences, with 66 cases in each group. The control group was given entecavir antiviral therapy, and the observation group was treated with Ganshuang particles combined with entecavir antiviral therapy. The clinical effects of the two groups were compared between the two groups. Results The total effective rate of the observation group was 95.5%, which was higher than 81.8% of the control group (P<0.05). After treatment, the levels of AST, ALB, ALT, TBIL, LN, PCⅢ, Ⅳ-C and HA of the two groups were better than those before treatment, and those of the observation group were better than the control group (P<0.05). Conclusion Gan shuang particles combined with entecavir in patients wih hepatitis B cirrhosis can significantly improve the liver function, it has satisfactory clinical effect, which is worthy of clinical application and promotion.
KEYWORDS: Ganshuang particles; entecavir; hepatitis B cirrhosis
参考文献：
[1] 张耀武.恩替卡韦分散片联合肝爽颗粒治疗失代偿期乙型肝炎肝硬化患者临床观察[J].实用肝脏病杂志,2013,16(6):550-551.
[2] 王双.恩替卡韦分散片联合肝爽颗粒对失代偿期乙型肝炎肝硬化的治疗价值分析[J].中国继续医学教育,2016,8(9):179-180.
[3] 费卫东.恩替卡韦分散片联合肝爽颗粒治疗失代偿期乙型肝炎肝硬化患者的临床疗效分析[J].吉林医学,2015,36(1):79-80.
[4] 张萍.分析乙肝肝硬化失代偿期患者应用恩替卡韦抗病毒治疗的临床效果及安全性[J].世界最新医学信息文摘:连续型电子期刊,2016,16(33):94-96.
[5] 田翠峰,吕乃达.肝爽颗粒联合恩替卡韦治疗慢性乙型肝炎纤维化的临床观察[J].内蒙古中医药,2015,34(7):72-73.
[6] 张悦.恩替卡韦联合维生素E 治疗乙型肝炎肝硬化患者肝纤维化指标的临床研究[J].山西医药杂志,2015,44(13):1527-1529.